Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
Abstract
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found on the ASCO Publications website .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Sonam Puri
Nofisat Ismaila
American Society of Clinical Oncology (ASCO), Alexandria, VA, US
Ibrahim Hanna Azar
IHA Hematology Oncology Consultants, Ypsilanti, MI
Janet Freeman-Daily
The ROS1ders, Seattle, WA
Naoki Furuya
St Marianna University School of Medicine, Kawasaki, Japan
Sara Kuruvilla
London Health Sciences Centre, London, ON, Canada
Logan Roof
Ohio State University, Columbus, OH
Ana I. Velazquez
Yubao Wang
Department of Cancer Biology, Dana-Farber Cancer Institute
Paul Wheatley Price
The Ottawa Hospital Research Institute/University of Ottawa, Ottawa, ON, Canada
Natasha B. Leighl